Reports Indicate Psychedelic Medicine Could be Better Investing Opportunity Than Cannabis

Financialnewsmedia.com News Commentary

PALM BEACH, Florida, July 15, 2020 /PRNewswire/ -- Over the last few years, all the talk has been about cannabis, cannabis… cannabis. CBD, CBG, THC and so on… but recent reports see the spotlight moving onto a different new "old" player. Its been said in a recent article that: "The global march toward cannabis legalization has seemingly awoken another long dormant area of scientific interest: psychedelics as medicine. While the idea of using LSD, MDMA, and psilocybin (the main hallucinogenic compound in magic mushrooms) to treat mental health disorders is far from a trail-blazing concept, this whole area of research had been off limits for the better part of the last 50 years. Then, something strange happened… In 2018, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) (for) psilocybin therapy for treatment-resistant depression. A few months later, the agency awarded (another) BTD for psilocybin therapy for major depressive disorder. In lockstep with the FDA's more open-minded approach toward psychedelic medicine, Denver, Oakland, and Santa Cruz all decided to decriminalize magic mushrooms. Hundreds of other U.S. cities are reportedly considering similar measures at the moment." Mentioned in today's commentary include:  Global Trac Solutions, Inc. (OTCPK: PSYC), Champignon Brands Inc. (OTCQB: SHRMF) (CSE: SHRM), The Yield Growth Corp. (OTCQB: BOSQF) (CSE: BOSS), Mind Medicine (MindMed) Inc. (OTCQB: MMEDF) (NEO: MMED), Mota Ventures Corp. (OTCPK: PEMTF) (CSE: MOTA).

The article stated it is a new era in psychedelic medicine, saying: "This renewed interest in psychedelics is being sparked by a pair of seemingly unrelated events. First up, cannabis has now been scientifically validated as a treatment for two severe forms of childhood epilepsy (more on this in a moment). These pioneering efforts with cannabis as medicine, in turn, have inspired researchers to take a second look at other controversial compounds like psilocybin. What's important to understand is that a paradigm shift is starting to be taking shape within the Western medical community. In effect, scientists are increasingly intrigued by the therapeutic potential of psychedelics as treatments for a whole range of mental health disorders. Psychedelic medicine thus has the potential to be a gold mine for early investors."